EpiAxis enters agreement with Seattle Children’s Research Institute
EpiAxis Therapeutics has signed a material transfer agreement (MTA) with Seattle Children’s Research Institute that will help researchers study a new approach to treating paediatric brain cancer. As part of the agreement, EpiAxis Therapeutics will supply its lead...
EpiAxis joins Tech Tuesday panel discussion
EpiAxis Therapeutics CEO Dr Jeremy Chrisp this week joined Tech Tuesdays, a Canadian Securities Exchange virtual showcase that features in-depth discussions with companies shaking up the technology industry. The episode - Precision Medicine in Cancer Treatment - was a...
EpiAxis presents at BioPharm America 2022
EpiAxis Therapeutics recently presented at BioPharm America 2022, part of Biotech Week Boston, giving investors an update on the company's progress in the epigenetic space. BioPharm America is a conference where the new wave of life science innovators partner to fuel...
There is currently no therapy to fight recurrent, metastatic breast cancer, which is the major source of death in women with breast cancer. Furthermore, current first-line treatments have extensive side-effects.We are determined to fix that.
Professor Sudha Rao
Founder at EpiAxis Therapeutics